These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18044031)

  • 1. Macular degeneration.
    Stevenson B; Siderov J
    Aust Fam Physician; 2007 Oct; 36(10):791. PubMed ID: 18044031
    [No Abstract]   [Full Text] [Related]  

  • 2. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
    Klein RM; Klein RB
    Retina; 2007; 27(9):1163-5. PubMed ID: 18046218
    [No Abstract]   [Full Text] [Related]  

  • 3. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF; Paloma JB
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract]   [Full Text] [Related]  

  • 4. Avastin versus Lucentis: ethical issues.
    Wong HC
    Retina; 2008; 28(7):1024-5; author reply 1025. PubMed ID: 18698312
    [No Abstract]   [Full Text] [Related]  

  • 5. A very effective treatment for neovascular macular degeneration.
    Stone EM
    N Engl J Med; 2006 Oct; 355(14):1493-5. PubMed ID: 17021326
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

  • 7. Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.
    Kimmelman J
    Retina; 2007; 27(9):1166-7. PubMed ID: 18046219
    [No Abstract]   [Full Text] [Related]  

  • 8. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
    Schmucker C; Antes G; Lelgemann M
    Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab.
    Yoon YH; Kim JG; Chung H; Lee SY
    Acta Ophthalmol; 2009 Sep; 87(6):685-7. PubMed ID: 18705680
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB; Tao Y; Rensch F
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab local complications.
    Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V
    Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862
    [No Abstract]   [Full Text] [Related]  

  • 12. Avastin and new treatments for AMD: where are we?
    Freeman WR; Falkenstein I
    Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
    [No Abstract]   [Full Text] [Related]  

  • 13. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.
    Quiroz-Mercado H; Ustariz-González O; Martinez-Castellanos MA; Covarrubias P; Dominguez F; Sanchez-Huerta V
    Semin Ophthalmol; 2007; 22(2):109-25. PubMed ID: 17564934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F; Eid Farah M; Melo GB
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract]   [Full Text] [Related]  

  • 15. [New drug treatment for age-related macular degeneration].
    Stefánsson E; la Cour M; Helgadóttir G; Sigurdsson H; Jónasson F
    Laeknabladid; 2007 Apr; 93(4):299-301. PubMed ID: 17460341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab: a new way of doing business?
    Canning C; Lotery A
    Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal avastin: the low cost alternative to lucentis?
    Rosenfeld PJ
    Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab.
    Lucas RS; McKee HD; Lee LR
    Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
    [No Abstract]   [Full Text] [Related]  

  • 20. Ranibizumab and stroke.
    Ueta T; Yanagi Y; Tamaki Y; Yamaguchi T
    Ophthalmology; 2010 Sep; 117(9):1860; author reply 1860-1. PubMed ID: 20816253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.